Converting a peptide into a drug: Strategies to improve stability and bioavailability

被引:514
作者
Adessi, C [1 ]
Soto, C [1 ]
机构
[1] Serono Pharmaceut Res Inst, Geneva, Switzerland
关键词
D O I
10.2174/0929867024606731
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 [生物化学与分子生物学]; 081704 [应用化学];
摘要
The discovery of peptide hormones, growth factors and neuropeptides implicated in vital biological functions of our organism has increased interest in therapeutic use of short peptides. However, the development of peptides as clinically useful drugs is greatly limited by their poor metabolic stability and low bioavailability, which is due in part to their inability to readily cross membrane barriers such as the intestinal and blood-brain barriers. The aim of peptide medicinal chemistry is, therefore, to develop strategies to overcome these problems. Recent progress in chemical synthesis and design have resulted in several strategies for producing modified peptides and mimetics with lower susceptibility to proteolysis and improved bioavailability, which has increased the probability of obtaining useful drugs structurally related to parent peptides, This review describes different experimental approaches to transforming a peptide into a potential drug and provides examples of the usefulness of these strategies.
引用
收藏
页码:963 / 978
页数:16
相关论文
共 161 条
[1]
CNS EFFECTS OF PEPTIDES - A CROSS-LISTING OF PEPTIDES AND THEIR CENTRAL ACTIONS PUBLISHED IN THE JOURNAL, PEPTIDES, 1986-1993 [J].
AHMED, B ;
KASTIN, AJ ;
BANKS, WA ;
ZADINA, JE .
PEPTIDES, 1994, 15 (06) :1105-1155
[2]
RELATIVE STABILITY OF ALPHA-MELANOTROPIN AND RELATED ANALOGS TO RAT-BRAIN HOMOGENATES [J].
AKIYAMA, K ;
YAMAMURA, HI ;
WILKES, BC ;
CODY, WL ;
HRUBY, VJ ;
CASTRUCCI, AMD ;
HADLEY, ME .
PEPTIDES, 1984, 5 (06) :1191-1195
[3]
Peptide and peptidomimetic libraries - Molecular diversity and drug design [J].
Al-Obeidi, E ;
Hruby, VJ ;
Sawyer, TK .
MOLECULAR BIOTECHNOLOGY, 1998, 9 (03) :205-223
[4]
Balaram P., 1992, CURR OPIN STRUC BIOL, V2, P845, DOI [DOI 10.1016/0959-440X(92)90110-S, 10.1016/0959-440X(92)90110-S]
[5]
PERMEABILITY OF THE BLOOD-BRAIN-BARRIER TO NEUROPEPTIDES - THE CASE FOR PENETRATION [J].
BANKS, WA ;
KASTIN, AJ .
PSYCHONEUROENDOCRINOLOGY, 1985, 10 (04) :385-399
[6]
Banks WA, 1996, ANN NY ACAD SCI, V805, P270
[7]
BARCHASE JD, 1986, NEUROPEPTIDES NEUROL, P287
[8]
STRUCTURAL REQUIREMENTS FOR OPIOID ACTIVITY OF ANALOGS OF ENKEPHALINS [J].
BEDDELL, CR ;
CLARK, RB ;
HARDY, GW ;
LOWE, LA ;
UBATUBA, FB ;
VANE, JR ;
WILKINSON, S ;
CHANG, KJ ;
CUATRECASAS, P ;
MILLER, RJ .
PROCEEDINGS OF THE ROYAL SOCIETY SERIES B-BIOLOGICAL SCIENCES, 1977, 198 (1132) :249-265
[9]
Begley DJ, 2000, BLOOD-BRAIN BARRIER AND DRUG DELIVERY TO THE CNS, P93
[10]
ENKEPHALIN PSEUDOPEPTIDES - RESISTANCE TO INVITRO PROTEOLYTIC DEGRADATION AFFORDED BY AMIDE BOND REPLACEMENTS EXTENDS TO REMOTE SITES [J].
BENOVITZ, DE ;
SPATOLA, AF .
PEPTIDES, 1985, 6 (02) :257-261